Phaseline

Targets › RS1

RS1 (Retinoschisin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Other; next expected readout Apr 2028.

Binds negatively charged membrane lipids, such as phosphatidylserine and phosphoinositides (By similarity). May play a role in cell-cell adhesion processes in the retina, via homomeric interaction between octamers present on the surface of two neighboring cells. (UniProt, O15537)

Open in Phaseline: the race on RS1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Atsena TherapeuticsATSN-201
AAV gene therapy delivering hRS1 under hGRK1 promoter
RS1Phase 3X-linked RetinoschisisApr 2028

Conditions

X-linked Retinoschisis (1)

Modalities

protein or peptide (1)

Companies

Atsena Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.